Last week, professor and Nobel Laureate Robert Shiller came out with a statement regarding the market high valuation. He referred to the CAPE ratio which is at 29 at the moment and is considered high. However, he also said that the high CAPE ratio does not necessarily mean investors should sell stocks right now.
Still, Shiller makes it clear this doesn’t necessarily suggest that investors should sell stocks.
“I’m not saying pull out of the market — I’m saying that it looks dangerous now,” the Yale economics professor said Wednesday on CNBC’s “Trading Nation.” “But it could keep going up.” Read more

Shiller PE Ratio as of May 3, 2017. Source: www.multpl.com/shiller-pe/
So the question is, once again, how can investors protect their portfolios at a reasonable price and still be able to participate on the upside?
One solution is to employ a hedging strategy such as the US Equity Portfolio Enhancement Trade that uses listed options.
Another solution is to use a proxy hedge. Such a solution was suggested recently by another academic giant, Jeremy Siegel.
Prominent stock-market bull Jeremy Siegel says the best bet in a severe market downturn may be owning 30-year, U.S. government paper.
“And don’t forget, the long bond is the ultimate hedge against a stock-market crash. If there’s going to be a bad event internationally, North Korea, Europe or whatever, everyone runs to the long bond,” the University of Pennsylvania economist and professor of finance at the Wharton School of Business told CNBC during a Monday interview.
“It’s an insurance policy, it gives [the bond] a premium and a premium means a low yield on that instrument,” he said. “If something happens, they will go up if the stock market goes down 500 points.” Read more
Right now, investors appear fearless as they are pouring money into equities. But they have forgotten that hedging is like buying insurance. And the best time to buy insurance is when we don’t need it. When the house catches fire, it will be too late to buy an insurance policy, or we have to pay an exorbitant price for it.
Further questions
What's your question? Ask it in the discussion forum
Have an answer to the questions below? Post it here or in the forum

Company to be in San Francisco January 8-12, 2023, during 41st Annual J.P. Morgan Health Care Conference WOBURN, Mass. and HAIFA, Israel, Jan. 03, 2023 (GLOBE NEWSWIRE) — Minovia Therapeutics, a clinical-stage global biotechnology company, today announced that the Company will be presenting at the Biotech…

King Dollar’s reign (definitely) coming to an end, bonds bouncing and emerging markets rising again are just some of the trades international money managers are betting on in 2023. Sky-high inflation and the global gut-punch of nearly 300 central bank interest rate hikes over the…

Masimo SpHb Demonstrated “Clinically Acceptable Accuracy” of Hemoglobin Measurement, Even at Low Hemoglobin Levels NEUCHATEL, Switzerland — Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in the Egyptian Journal of Anesthesia in which Dr. Mohamed Ibrahim Beleta and colleagues at Cairo…

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan & LONDON — Gensource Potash Corporation (“Gensource” or the “Company”) (AIM/TSXV: GSP), a fertilizer development company focused on sustainable potash production, today announced that on December 30, 2022, it…